Research Papers:

Hyperinsulinemia enhances interleukin-17-induced inflammation to promote prostate cancer development in obese mice through inhibiting glycogen synthase kinase 3-mediated phosphorylation and degradation of interleukin-17 receptor

Sen Liu, Qiuyang Zhang, Chong Chen, Dongxia Ge, Yine Qu, Rongyi Chen, Yi-Ming Fan, Nan Li, Wendell W. Tang, Wensheng Zhang, Kun Zhang, Alun R. Wang, Brian G. Rowan, Steven M. Hill, Oliver Sartor, Asim B. Abdel-Mageed, Leann Myers, Qishan Lin and Zongbing You _

PDF  |  HTML  |  Supplementary Files  |  How to cite

Oncotarget. 2016; 7:13651-13666. https://doi.org/10.18632/oncotarget.7296

Metrics: PDF 2597 views  |   HTML 6106 views  |   ?  


Sen Liu1,*, Qiuyang Zhang1,*, Chong Chen1, Dongxia Ge1, Yine Qu1, Rongyi Chen2, Yi-Ming Fan2, Nan Li2, Wendell W. Tang3, Wensheng Zhang4, Kun Zhang4, Alun R. Wang5, Brian G. Rowan1,6,7, Steven M. Hill1,6, Oliver Sartor6,8,9, Asim B. Abdel-Mageed6,8, Leann Myers10, Qishan Lin11, Zongbing You1,6,7,12

1Department of Structural and Cellular Biology, Tulane University, New Orleans, LA 70112, USA

2Department of Dermatology, Affiliated Hospital of Guangdong Medical College, Zhanjiang, Guangdong 524001, China

3Department of Pathology, Ochsner Clinic Foundation, New Orleans, LA 70130, USA

4Department of Computer Science and Biostatistics Facility of RCMI Cancer Research Center, Xavier University of Louisiana, New Orleans, LA 70125, USA

5Department of Pathology and Laboratory Medicine, Tulane University, New Orleans, LA 70112, USA

6Tulane Cancer Center, Louisiana Cancer Research Consortium, Tulane University, New Orleans, LA 70112, USA

7Tulane Center for Stem Cell Research and Regenerative Medicine, Tulane University, New Orleans, LA 70112, USA

8Department of Urology, Tulane University, New Orleans, LA 70112, USA

9Department of Medicine, Tulane University, New Orleans, LA 70112, USA

10Department of Biostatistics and Bioinformatics, Tulane University, New Orleans, LA 70112, USA

11Proteomics/Mass Spectrometry Facility, University at Albany, Rensselaer, NY 12144, USA

12Department of Orthopaedic Surgery and Tulane Center for Aging, Tulane University, New Orleans, LA 70112, USA

*These authors contributed equally to this work

Correspondence to:

Zongbing You, e-mail: [email protected]

Keywords: hyperinsulinemia, obesity, prostate cancer, interleukin-17, GSK3

Received: December 02, 2015     Accepted: January 29, 2016     Published: February 10, 2016


Interleukin-17 (IL-17) plays important roles in inflammation, autoimmune diseases, and some cancers. Obese people are in a chronic inflammatory state with increased serum levels of IL-17, insulin, and insulin-like growth factor 1 (IGF1). How these factors contribute to the chronic inflammatory status that promotes development of aggressive prostate cancer in obese men is largely unknown. We found that, in obese mice, hyperinsulinemia enhanced IL-17-induced expression of downstream proinflammatory genes with increased levels of IL-17 receptor A (IL-17RA), resulting in development of more invasive prostate cancer. Glycogen synthase kinase 3 (GSK3) constitutively bound to and phosphorylated IL-17RA at T780, leading to ubiquitination and proteasome-mediated degradation of IL-17RA, thus inhibiting IL-17-mediated inflammation. IL-17RA phosphorylation was reduced, while the IL-17RA levels were increased in the proliferative human prostate cancer cells compared to the normal cells. Insulin and IGF1 enhanced IL-17-induced inflammatory responses through suppressing GSK3, which was shown in the cultured cell lines in vitro and obese mouse models of prostate cancer in vivo. These findings reveal a mechanism underlying the intensified inflammation in obesity and obesity-associated development of aggressive prostate cancer, suggesting that targeting GSK3 may be a potential therapeutic approach to suppress IL-17-mediated inflammation in the prevention and treatment of prostate cancer, particularly in obese men.

Creative Commons License All site content, except where otherwise noted, is licensed under a Creative Commons Attribution 4.0 License.
PII: 7296